Pre-Course Assessment

Pre- Pharmacogenomics: From Genetic Variants to Personalized Therapeutics

MM slash DD slash YYYY
Exam Timer
Timer: 00:15:00

SESSION EXPIRED

The 15 minutes have ended.

Participant Name:(Required)

1. Age (years)(Required)

2. Where do you live?(Required)

3. Medical background(Required)

4. Employ status(Required)

5. Major working area(Required)

6. How did you know about this workshop?(Required)

The below questions are to evaluate the participant’s knowledge about pharmacogenomics testing before taking this workshop:

7. Inherited genetic variants may influence the drug response(Required)

8. Inter-individual variation in response to drugs and toxicity may be due to inherited genetic variants(Required)

9. There is no inter-ethnic variation in the drug response(Required)

10. Inter-individual variation in pharmacokinetic parameters may be due to genetic variations(Required)

11. Inter-individual variation in pharmacodynamics may be due to genetic variations(Required)

12. Some patients have a high risk of drug toxicity due to inherited genetic variants(Required)

13. Some patients do not respond to medicines due to some inherited variants(Required)

14. The drug response can be always predicted using genetic biomarkers(Required)

15. CYP3A4 variants may affect metabolism and, hence, the warfarin response(Required)

16. VKORC1 variants may affect the pharmacodynamics and, hence, the warfarin response(Required)

17. CYP2C19 and 2D6 variants may affect the dosing of the antidepressant drugs(Required)

18. Genetic variants in endothelial growth 19. factor receptors affects the response to Tamoxifen(Required)

19. FDA does not provides clinical evidence for pharmacogenomics testing in the labeling of many drugs(Required)

20. Polyphen2 software can predict the effect of genetic variants on the drugs response(Required)

21. The cost of pharmacogenomics testing can be one of the major barriers against the implementation of pharmacogenomics testing in the clinical practice(Required)